Melinta Therapeutics, Inc., a commercial-stage company focused on the development and commercialization of novel antibiotics, has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020.

In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. Melinta expects to build upon its existing platform and enhance its antibiotics portfolio with additional products that address therapeutic areas of critical need.

Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. Most recently, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was accountable for transitioning the portfolio toward rapid-growth and higher-margin segments, such as complex generics and value-added medicines, while continuing to build the branded generics business.

“We are pleased that Christine will be joining Melinta at this pivotal moment,” said Deerfield Partner and Melinta Board Member Jonathan Leff.  “Christine’s deep industry knowledge, successful track record, and outstanding leadership, will help Melinta to fulfill its mission in the fight against drug-resistant infections and to grow its business in other areas of high unmet need.”